To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: AZD8233 subcutaneous injection
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]